The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): stu
about
The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): stu
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
The role of ixazomib as an aug ...... K-MRA Myeloma XII] trial): stu
@en
The role of ixazomib as an aug ...... utologous stem cell transplant
@nl
type
label
The role of ixazomib as an aug ...... K-MRA Myeloma XII] trial): stu
@en
The role of ixazomib as an aug ...... utologous stem cell transplant
@nl
prefLabel
The role of ixazomib as an aug ...... K-MRA Myeloma XII] trial): stu
@en
The role of ixazomib as an aug ...... utologous stem cell transplant
@nl
P2093
P2860
P6366
P1154
2-s2.0-85043376971
P1433
P1476
The role of ixazomib as an aug ...... K-MRA Myeloma XII] trial): stu
@en
P2093
A John Ashcroft
Alina Striha
Anna Hockaday
Gordon Cook
Gwen Jacques
Jamie Cavenagh
John A Snowden
Karen Boardman
Mamta Garg
P2860
P2888
P356
10.1186/S13063-018-2524-8
P577
2018-03-07T00:00:00Z
P6179
1101375562
P6366
2797277339